Table 2.
Comparison of two risk-category-specific screening intervals with the uniform 5-year screening interval
| 5-5-5 screening interval* | 10-5-2 screening interval* | 7-4-1 screening interval* | ||
|---|---|---|---|---|
| Number of people at low or intermediate risk at baseline | 6545 | 6545 | 6545 | |
| Number of person-years spent unidentified in high-risk category | 7866 (7130 to 8658) | 5339 (4885 to 5827) | 2973 (2681 to 3292) | |
| Difference in person-years spent unidentified in high-risk category | 0 (reference) | −2527 (−2831 to −2245) | −4894 (−5366 to −4449) | |
| Number of major cardiovascular events prevented | 0 (reference) | 25 (22 to 28) | 49 (44 to 54) | |
| Number of adverse events caused across the study period | ||||
| Diabetes | 0 (reference) | 3·79 (3·37 to 4·25) | 7·34 (6·67 to 8·05) | |
| Haemorrhagic stroke | 0 (reference) | 0·38 (0·34 to 0·42) | 0·73 (0·67 to 0·80) | |
| Myopathy | 0 (reference) | 0·25 (0·22 to 0·28) | 0·49 (0·44 to 0·54) | |
| Number of QALYs gained | 0 (reference) | 23 (20 to 26) | 44 (40 to 49) | |
| Costs (thousands, £)† | ||||
| Health-check costs | 437 (428 to 445) | 412 (400 to 425) | 658 (627 to 693) | |
| Costs saved owing to earlier prevention with statin | 0 (reference) | −120 (−134 to −106) | −232 (−254 to −211) | |
| Total costs (health-check costs − savings) | 437 (428 to 445) | 292 (291 to 294) | 427 (416 to 439) | |
| Total costs compared with 5-5-5 screening interval | 0 (reference) | −144 (−154 to −134) | −10 (−12 to −7) | |
Data are estimate (95% CI), unless otherwise specified. Figures are estimated for a 20-year period. QALY=quality-adjusted life-year.
In years for low-risk, intermediate-low-risk, and intermediate-high-risk individuals (95% CI).
In the Whitehall II cohort of adults aged 40–64 years at baseline. Cost of £18·39 per health check derived from Kypridemos and colleagues19 and costs and QALYs gained with preventive statin treatment (£47·33 and 0·00906 QALYs gained per person-year under statin treatment compared with placebo) derived from Collins and colleagues20 and from the West of Scotland Coronary Prevention Study.21 The number of adverse events estimated based on incidence estimates of 0·0015, 0·00015, and 0·00010 for diabetes, haemorrhagic stroke, and myopathy20 among those who would have received statin treatment.